PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Go online to PeerView.com/DUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the management of anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia because of CKD, Compare current and emerging treatments for CKD-associated anemia in terms of their mechanisms of action, efficacy, and safety, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/YPD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiology discusses the risk factors and symptoms associated with hyperkalemia and provides strategies to identify and manage these patients as well as methods for incorporating newer treatment options based on the latest evidence. Upon completion of this activity, participants should be better able to: Recognize the risk factors and clinical signs and symptoms associated with hyperkalemia, Identify different patient populations with or at risk for hyperkalemia and management strategies that address their specific needs and clinical goals of care, Incorporate newer treatment options for hyperkalemia management, including among patients with diabetes, heart failure, and chronic kidney disease (CKD), based on the latest evidence

Go online to PeerView.com/AZE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Approximately 20% of patients with asthma have uncontrolled, moderate to severe disease with recurrent exacerbations and persistent symptoms despite maximized standard-of-care controller therapy. Many of these patients have substantially reduced lung function and continue to lose lung function over time. About 50% of those with asthma have type 2 (T2) inflammation, which is mediated by cytokines such as interleukin (IL)-4, IL-5, and IL-13. Novel biologic agents that target T2 cytokines have shown efficacy and safety in these patients and are now available, with others in development, providing clinicians with more opportunities to personalize therapy for patients with severe asthma. In this activity, based on a recent symposium held in New Orleans, experts in pulmonology share actual patient stories to illustrate the recognition and burden of severe asthma in patients, as well as discuss best practices and strategies for managing this condition and facilitating effective collaboration with patients to actively engage them in their own care. Upon completion of this activity, participants should be better able to: Discuss the inflammatory mediators and mechanisms that provide the basis for the phenotypes and endotypes of severe asthma and their relevance to novel biologic therapies, Evaluate patients with asthma for symptom severity, disease phenotypes, exacerbation risk, and eligibility for biologic therapies, Apply evidence-based guidelines and the latest clinical data when selecting treatment for patients with severe asthma, Use strategies to communicate effectively with patients about self-management and to improve inhaler technique, adherence, and overall quality of life in patients with severe asthma

Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology

Go online to PeerView.com/RNV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in heart failure discusses the early diagnosis and management of CHF. Upon completion of this activity, participants should be better able to: Implement evidence-based guidelines for early recognition and diagnosis of CHF, Apply available CHF therapies based on ACC/AHA/HFSA guidelines and clinical efficacy and safety data, Employ strategies to promote adherence to therapy and lifestyle modifications among patients with CHF

Go online to PeerView.com/FWN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in pulmonology discuss strategies for overcoming challenges in the management of severe asthma and the role of targeted therapies in personalized care. Upon completion of this activity, participants should be better able to: Explain the role of inflammatory mediators and mechanisms in the pathogenesis of severe asthma and in the context of treatment targets, Summarize the latest clinical data related to efficacy and safety for currently available and emerging treatments for severe asthma, Create treatment plans for patients with severe asthma based on the latest guidelines and efficacy and safety data, disease severity, phenotype/endotype, and patient preferences, Employ patient education and communication strategies to improve inhaler technique, patient adherence, self-management, and overall quality of life in patients with severe asthma

Go online to PeerView.com/XHY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in dermatology and pediatric primary care discuss the management of patients with atopic dermatitis. A patient also joins the discussion to provide unique perspectives on living with atopic dermatitis and interacting with healthcare providers. Upon completion of this activity, participants should be better able to: Diagnose atopic dermatitis in individual patients based on recognition of clinical manifestations and application of current diagnostic criteria and guidelines, Describe the mechanisms of action and clinical profiles of new and emerging topical and systemic therapies for atopic dermatitis, Select appropriate treatments for patients with atopic dermatitis based on current guideline recommendations, the safety and efficacy of available treatment options, comorbidities, and burden of disease, Employ shared decision-making approaches to create individualized treatment plans for atopic dermatitis, Implement patient/caregiver education strategies to improve adherence to atopic dermatitis treatment (eg, managing application-site pain associated with topical therapies) and assess the effects of treatment on patient quality of life

Go online to PeerView.com/YAX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Optimal management of chronic obstructive pulmonary disease (COPD) begins with accurate diagnosis and ongoing, appropriate assessment of disease severity. The burden of COPD, and its associated morbidity and mortality, are not always recognized, and underdiagnosis remains prevalent. A personalized, evidence-based approach to the management of patients with COPD, including the selection of treatment based on various factors such as patient symptomatology, comorbidities, exacerbation risk, choice of inhalation device, and phenotypic characteristics, can help healthcare providers in guiding their patients down a path to successful treatment. Proper technique and adherence, as well as involving the patient in the creation of a COPD action plan and goal setting, so they may better manage COPD in their everyday life, are also key elements in a patient’s journey with COPD. In this activity, our expert panel explores the use of evidence-based guidelines in diagnosing patients and the therapeutic role of eosinophils. In addition, the panel discusses the creation of treatment plans, proper inhaler technique, and the importance of adherence for patients with COPD. Upon completion of this activity, participants should be better able to: Employ evidence-based guidelines to accurately diagnose and monitor patients with chronic obstructive pulmonary disease (COPD), Discuss the potential role of eosinophils in selecting maintenance therapy for patients with COPD, Create maintenance treatment plans for patients with COPD, based on factors including efficacy, safety, patient symptomatology, comorbidities, and exacerbation risk, Apply strategies to ensure proper inhaler use and encourage goal setting and medication adherence for patients with COPD

Go online to PeerView.com/WGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses strategies to optimize the care of patients with chronic spontaneous urticaria in the primary care setting. Upon completion of this activity, participants should be better able to: Recognize the clinical presentation of chronic spontaneous urticaria and its impact on patient quality of life, Employ evidence-based guidelines to accurately diagnose patients with chronic spontaneous urticaria, Apply therapeutic options for treating chronic spontaneous urticaria in the context of available evidence and current treatment algorithms, Assess key data sets on the efficacy and safety of emerging pharmacologic treatments for chronic spontaneous urticaria

Go online to PeerView.com/XHY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in dermatology and pediatric primary care discuss the management of patients with atopic dermatitis. A patient also joins the discussion to provide unique perspectives on living with atopic dermatitis and interacting with healthcare providers. Upon completion of this activity, participants should be better able to: Diagnose atopic dermatitis in individual patients based on recognition of clinical manifestations and application of current diagnostic criteria and guidelines, Describe the mechanisms of action and clinical profiles of new and emerging topical and systemic therapies for atopic dermatitis, Select appropriate treatments for patients with atopic dermatitis based on current guideline recommendations, the safety and efficacy of available treatment options, comorbidities, and burden of disease, Employ shared decision-making approaches to create individualized treatment plans for atopic dermatitis, Implement patient/caregiver education strategies to improve adherence to atopic dermatitis treatment (eg, managing application-site pain associated with topical therapies) and assess the effects of treatment on patient quality of life